CD7 and acute lymphoblastic leukemia: In a recently reported phase I trial, 20 patients with relapsed/refractory T-ALL treated with anti-CD7 CAR-T-cells achieved a high complete remission rate of 90%, and most of these patients remained in remission with a median follow-up of 6.3 months [33].